Please login to the form below

Not currently logged in
Email:
Password:

Tregs

This page shows the latest Tregs news and features for those working in and with pharma, biotech and healthcare.

Syncona start-up Quell Therapeutics appoints chief exec

Syncona start-up Quell Therapeutics appoints chief exec

Biotech focusing on Tregs. Quell Therapeutics, a new UK biotech company focused on developing engineered T regulatory (Treg) cell therapies, has appointed Iain McGill as its chief executive. ... London-based Quell Therapeutics aims to harness this

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Although described as an acquisition, the deal covers two products, including an anti-CD25 antibody that depletes regulatory T‐cells (Tregs) while preserving IL‐2 binding and signalling on effector ... Tregs) while preserving effector T‐cells (Teffs

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics